Search Results - "Seifert, Randall D"

Measuring Frailty Using Patient-Reported Outcomes (PRO) Data: A Feasibility Study in Patients with Multiple Myeloma by Murugappan, Meena N., King-Kallimanis, Bellinda L., Bhatnagar, Vishal, Kanapuru, Bindu, Farley, Joel F., Seifert, Randall D., Stenehjem, David D., Chen, Ting-Yu, Horodniceanu, Erica G., Kluetz, Paul G.

“…Purpose The objective of this retrospective study was to determine the feasibility of measuring frailty using patient responses to relevant EORTC QLQ-C30 items…”
Get full text

Examining Medicare Part D Medication Therapy Management program in the context of mental health by Murugappan, Meena N., Seifert, Randall D., Farley, Joel F.

“…To describe and compare the delivery of medication therapy management (MTM) between Medicare beneficiaries with and without mental health conditions…”
Get full text

Reprint of: Examining Medicare Part D Medication Therapy Management program in the context of mental health by Murugappan, Meena N., Seifert, Randall D., Farley, Joel F.

“…To describe and compare the delivery of medication therapy management (MTM) between Medicare beneficiaries with and without mental health conditions…”
Get full text

Pharmacogenomics education, research and clinical implementation in the state of Minnesota by Bishop, Jeffrey R, Huang, R Stephanie, Brown, Jacob T, Mroz, Pawel, Johnson, Steven G, Allen, Josiah D, Bielinski, Suzette J, England, Julie, Farley, Joel F, Gregornik, David, Giri, Jyothsna, Kroger, Christine, Long, Susie E, Luczak, Tiana, McGonagle, Erin J, Ma, Sisi, Matey, Eric T, Mandic, Pinar K, Moyer, Ann M, Nicholson, Wayne T, Petry, Natasha, Pawloski, Pamala A, Schlichte, Allyson, Schondelmeyer, Stephen W, Seifert, Randall D, Speedie, Marilyn K, Stenehjem, David, Straka, Robert J, Wachtl, Jason, Waring, Stephen C, Ness, Brian Van, Zierhut, Heather A, Aliferis, Constantin, Wolf, Susan M, McCarty, Catherine A, Jacobson, Pamala A

“…Several healthcare organizations across Minnesota have developed formal pharmacogenomic (PGx) clinical programs to increase drug safety and effectiveness…”
Get full text

Patient-reported frailty phenotype (PRFP) vs. International Myeloma Working Group frailty index (IMWG FI) proxy: A comparison between two approaches to measuring frailty by Murugappan, Meena N., King-Kallimanis, Bellinda L., Bhatnagar, Vishal, Kanapuru, Bindu, Farley, Joel F., Seifert, Randall D., Stenehjem, David D., Chen, Ting-Yu, Horodniceanu, Erica G., Kluetz, Paul G.

“…Frailty assessments may help to identify patients at highest risk for treatment-related toxicity, early treatment discontinuation due to toxicity, and death in…”
Get full text

Effect of cardiopulmonary bypass on cefazolin disposition by Miller, K W, McCoy, H G, Chan, K K, Fischer, R P, Lindsay, W G, Seifert, R D, Zaske, D E

“…Cefazolin kinetics was studied in 8 patients the day before (PREOP), during (SURG), and the day after (POSTOP) cardiopulmonary bypass (CPB) surgery. PREOP…”
Get more information

Acetylcholinesterase inhibition by zifrosilone: pharmacokinetics and pharmacodynamics by Cutler, N R, Seifert, R D, Schleman, M M, Sramek, J J, Szylleyko, O J, Howard, D R, Barchowsky, A, Wardle, T S, Brass, E P

“…To determine the pharmacokinetics, pharmacodynamics and safety of the acetylcholinesterase inhibitor zifrosilone in healthy male volunteers. Pharmacokinetics,…”
Get more information

The use of the Computerized Neuropsychological Test Battery (CNTB) in an efficacy and safety trial of BMY 21,502 in Alzheimer's disease by Cutler, N R, Shrotriya, R C, Sramek, J J, Veroff, A E, Seifert, R D, Reich, L A, Hironaka, D Y

“…BMY 21,502 is a nootropic which protects memory and enhances long-term potentiation according to preclinical findings. Alzheimer's disease (AD) patients who…”
Get more information

Heparin kinetics: variables related to disposition and dosage by Cipolle, R J, Seifert, R D, Neilan, B A, Zaske, D E, Haus, E

“…A method to determine heparin kinetics and dosage requirements was examined in 20 patients with active thromboembolic disease. Pretreatment heparin…”
Get more information

Management of Acute Coronary Syndrome and Venous Thromboembolism: A Managed Care Perspective by Seifert, Randall D.

Get full text

Applying Quality Measures and Guidelines in the Management of Acute Coronary Syndrome and Venous Thromboembolism by Gulseth, Michael P., Sobieszczyk, Piotr, Fanikos, John, Seifert, Randall D.

Get full text

Compliance in hypertension: daily v twice daily by Sramek, J J, Cutler, N R, Seifert, R D, Luna, A D

Get more information

Fleroxacin treatment of stage IV pressure ulcers with associated osteomyelitis by Cutler, N R, Seifert, R D, Sramek, J J, Boyd, W M, St Clair, P

Get more information

Heparin-induced thrombocytopenia in patients with cerebrovascular ischemic disease by RAMIREZ-LASSEPAS, M, CIPOLLE, R. J, RODVOLD, K. A, SEIFERT, R. D, STRAND, L, TADDEINI, L, CUSULOS, M

“…We studied 137 patients who were treated with heparin for cerebral infarction (73), partially reversible ischemic neurologic deficit (22), or transient…”
Get full text

Effect of sucralfate on the absorption and pharmacokinetics of chlorpropamide by Letendre, P W, Carlson, J D, Seifert, R D, Dietz, Jr, A J, Dimmit, D

“…This study compared the pharmacokinetics of chlorpropamide (C) when administered alone, or in combination with sucralfate (S) to evaluate whether a drug-drug…”
Get more information

Systematically individualizing tobramycin dosage regimens by Cipolle, R J, Seifert, R D, Zaske, D E, Strate, R G

“…Tobramycin dosage regimens were individually calculated from serum concentration-time data in 64 patients. Tobramycin pharmacokinetic parameters and dosage…”
Get more information

Hospital acquired gram-negative pneumonias: response rate and dosage requirements with individualized tobramycin therapy by Cipolle, R J, Seifert, R D, Zaske, D E, Strate, R G

“…Individualized tobramycin therapy was systemically evaluated in 26 patients with gram-negative pneumonias involving Pseudomonas aeruginosa and other multiple…”
Get more information

Comparison of quantitative methodologies to define chronic pressure ulcer measurements by Cutler, N R, George, R, Seifert, R D, Brunelle, R, Sramek, J J, McNeill, K, Boyd, W M

“…The objective of this study was to evaluate and compare various methodologies of measuring the characteristics of pressure ulcers. This prospective, four-week,…”
Get more information

Characteristics of heparin-associated thrombocytopenia by Rector, T S, Cipolle, R J, Seifert, R D, Ramirez-Lassepas, M

Get more information